Camp4 Therapeutics Corp (CAMP) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$3.33

From 52W high−55.96%

Volume57666.00

Market cap$197.05M

P/E (TTM)—

P/S (TTM)46.7x

Div yield—

Key dataOct 19, 2026

Open

$3.33

From 52W high

−55.96%

Volume

57666.00

Market cap

$197.05M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.5x

P/E (TTM)

—

RSI (14)

30.1

MomentumView details →

1D Return

−0.95%

YTD Return

−48.78%

SummaryUpdated Jun 1, 2026

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) is a biotechnology company founded in 2015 by renowned scientists Richard A. Young and Leonard Zon, headquartered in Cambridge, Massachusetts. The company went public in October 2024 through an initial public offering. CAMP4 operates as a clinical-stage biotechnology company focused on discovering and developing novel treatment options for patients with serious diseases through its proprietary regulatory RNA platform technology.

Ask drillr about Camp4 Therapeutics Corp →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.5x

EV/Sales

26.6x

P/S (TTM)

46.7x

P/B (TTM)

−284.3x

ProfitabilityView details →

Gross Margin

77.80%

Net Margin

−2543.74%

EBITDA Margin

−1723.27%

ROE (TTM)

—

ROA (TTM)

−114.79%

Asset Turnover

0.04x

GrowthView details →

Revenue YoY

+40.21%

EPS YoY

+15.21%

FCF YoY

+37.77%

Revenue CAGR 3Y

−77.20%

EPS CAGR 3Y

+0.38%

EBITDA YoY

−39.74%

MomentumView details →

1D Return

−0.95%

YTD Return

−48.78%

1Y Return

−1.57%

RSI (14)

30.1

vs 50D SMA

−23.27%

vs 200D SMA

−27.44%

Capital & dividendView details →

Debt/Equity

−3.42x

Current Ratio

4.70x

Quick Ratio

4.70x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.58

EPS Surprise

−174.32%

Beats (12Q)

3/12

Next Q EPS Est

−$0.19

Avg Surprise (4Q)

−81.91%

Rev Surprise

9.81%

Financials snapshotView financials →

Revenue (TTM)

4.22M

Net Income (TTM)

−107.24M

Op. CF (TTM)

−28.59M

Latest newsMore news →

The UK's Medicines and Healthcare products Regulatory Agency authorized CAMP4 Therapeutics to conduct a Phase 1/2 human clinical trial of CMP-002 in patients with SYNGAP1-related disorder.40d ago

CAMP4 Therapeutics Corporation reported a Q2 2026 loss of $0.22 per share, beating the Zacks Consensus Estimate of a $0.24 loss and improving from a $0.62 loss a year earlier.67d ago

Similar companies

Niagen Bioscience IncNAGE Evommune, Inc.EVMN Akebia Therapeutics, Inc.AKBA Entrada Therapeutics, Inc.TRDA PepGen Inc.PEPG Sutro Biopharma, Inc.STRO Find similar companies →

Latest newsMore news →

The UK's Medicines and Healthcare products Regulatory Agency authorized CAMP4 Therapeutics to conduct a Phase 1/2 human clinical trial of CMP-002 in patients with SYNGAP1-related disorder.40d ago CAMP4 Therapeutics Corporation reported a Q2 2026 loss of $0.22 per share, beating the Zacks Consensus Estimate of a $0.24 loss and improving from a $0.62 loss a year earlier.67d ago